Clinical Trials Logo

Clinical Trial Summary

To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD


Clinical Trial Description

a multi-center, randomized, double-blind, placebo-controlled, parallel-arm design, laboratory classroom (LC) clinical trial to evaluate the safety and efficacy of NRCT-101SR (up to to 2,000 mg/day based on LBM) over a 6-week period in approximately 160 pediatric subjects (13-17 years of age) with ADHD. An open label extension (OLE) of 6 weeks will be optional. Selected sites will collect blood samples for PK from a subset of subjects. The primary endpoint of the study is Permanent Product Measure of Performance (PERMP) Math Tests and the key secondary endpoint is ADHD Rating Scale (ADHD-RS). The primary analysis will be on effects of 6-week treatment of NRCT-101SR versus placebo on performance (PERMP) in subjects with ADHD. ;


Study Design


Related Conditions & MeSH terms

  • Attention Deficit Disorder with Hyperactivity
  • Attention-Deficit/Hyperactivity Disorder (ADHD)
  • Hyperkinesis

NCT number NCT06215144
Study type Interventional
Source Neurocentria, Inc.
Contact Mary Miller, MAOM
Phone 925-954-4868
Email mmiller@neurocentria.com
Status Recruiting
Phase Phase 2/Phase 3
Start date January 25, 2024
Completion date February 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT02150668 - Efficacy of an Organizational Skills Intervention for Middle School Students With ADHD N/A
Completed NCT00631280 - Does Active Parent Involvement in Deliberation and Choice Improve Medication Persistence for Their Child With ADHD N/A
Recruiting NCT05809388 - Virtual Reality for Parent Training Intervention N/A
Completed NCT00776009 - Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting. Phase 4
Recruiting NCT00252278 - Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents Phase 4
Completed NCT04016779 - Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD Phase 3
Completed NCT00307268 - Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adults With ADHD N/A
Completed NCT01107496 - Evaluation of Immediate-Release Viloxazine in Adults With ADHD Phase 1/Phase 2
Completed NCT04786990 - Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD Phase 4
Completed NCT00475735 - A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED) Phase 2
Completed NCT00711724 - Comparison of Self and Clinician Administered Rating Scales in Patients With ADHD N/A
Completed NCT02633527 - Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD Phase 2
Withdrawn NCT00323700 - A Naturalistic Prospective Study of Treatment Effectiveness for Attention-Deficit/Hyperactivity Disorder (ADHD) N/A
Not yet recruiting NCT04532190 - Finding Alternatives to Standard Treatment for Attention-Deficit Hyperactivity Disorder N/A
Withdrawn NCT00931398 - Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate Phase 4